Adjuvant programmed death-1 inhibition combined with chemotherapy in resected pancreatic cancer: A real-world cohort study

Table 1 Baseline characteristics of patients in the two treatment groups, n (%)

Variable	Chemo + PD-1 (n = 26)	Chemo (n = 31)	P value
Age (years), mean ± SD	57.3 ± 9.5	60.7 ± 8.5	0.169
Sex			0.059
Male	13 (50.0)	23 (74.2)
Female	13 (50.0)	8 (25.8)
BMI (kg/m²), mean ± SD	22.7 ± 3.0	22.1 ± 2.4	0.307
Smoking history	10 (38.5)	15 (48.4)	0.452
Alcohol use	8 (30.8)	9 (29.0)	0.886
Diabetes	5 (19.2)	4 (12.9)	0.721
Family history of cancer	2 (7.7)	0 (0.0)	0.291
ECOG performance status			0.217
0	22 (84.6)	21 (67.7)
1	4 (15.4)	10 (32.3)
Differentiation			0.884
High	1 (3.8)	1 (3.2)
Moderate	11 (42.3)	10 (32.3)
Poor	12 (46.2)	15 (48.4)
Tumor location			0.498
Head	19 (73.1)	25 (80.6)
Body/tail	7 (26.9)	6 (19.4)
T stage			0.673
T1	7 (26.9)	6 (19.4)
T2	18 (69.2)	22 (71.0)
T3	1 (3.8)	3 (9.7)
N stage			0.212
N0	21 (80.8)	19 (61.3)
N1	3 (11.5)	10 (32.3)
N2	2 (7.7)	2 (6.5)
AJCC stage			0.058
I	21 (80.8)	17 (54.8)
II	3 (11.5)	12 (38.7)
III	2 (7.7)	2 (6.5)
Time to adjuvant therapy (days), median (IQR)	45 (32.25-64)	39 (30-55)	0.718

T and N stages were classified according to the American Joint Committee on Cancer 8^th edition. Data are presented as mean ± SD for normally distributed continuous variables, median (interquartile range) for non-normally distributed variables, and number (percentage) for categorical variables. BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; AJCC: American Joint Committee on Cancer; IQR: Interquartile range; PD-1: Programmed death-1.